Miralles Gines Diego
President & Head of R&D
Miralles Gines Diego has filed 3 SEC Form 4 filings (3 transaction rows) across 1 company, with disclosures dating back to 2026. 3 of those filings fall inside the rolling window. Most recent filing: Nov 18, 2026.
On the most recent filing, Miralles Gines Diego is listed as President & Head of R&D at Artiva Biotherapeutics, Inc. Inside the rolling window, Miralles Gines Diego reported no open-market purchases and 1 open-market sale totaling $4K in ARTV.
Companies traded
Other insiders at ARTV
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$4K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Miralles Gines Diego made?
Miralles Gines Diego has filed 3 SEC Form 4 filings (3 transaction rows) across 1 company since 2026.
Which companies does Miralles Gines Diego trade?
Miralles Gines Diego has filed SEC Form 4 disclosures for 1 company, including ARTV.
When was Miralles Gines Diego's most recent SEC Form 4 filing?
Miralles Gines Diego's most recent SEC Form 4 filing on Tracefour is dated Nov 18, 2026.
What is Miralles Gines Diego's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Miralles Gines Diego is listed as President & Head of R&D.
What is Miralles Gines Diego's total buy and sell value in the current window?
Inside the rolling retention window, Miralles Gines Diego bought $0 and sold $4K based on SEC Form 4 filings.
What was Miralles Gines Diego's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 1,043 ARTV shares on 2026-11-17, worth $4K, per SEC Form 4 filings.